We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
10:00 AM
-
50 minsWith the emergence of megarounds in the past year, company leaders are wondering about the prospects for funding if their R&D is not in the most sought after therapeutic areas. Is it still possible to ...
11:00 AM
-
50 minsGLP-1 analogs have changed the game for many people living with obesity, but the medical community is looking for improvements in delivery, side effect profiles and more. This panel will examine how i ...
2:00 PM
-
50 minsA recent McKinsey analysis shows that first-time launches are projected to outnumber those from established companies by nearly two to one. As companies seek to move from the clinic to market, underst ...
3:00 PM
-
50 mins2024 saw a modest uptick compared to the past few years in successful biotech IPOs. In this panel, executives who survived the IPO gauntlet will share the lessons learned during the IPO process and th ...
4:00 PM
-
50 minsThe recent Nobel Prize recognition of AI’s ability to model molecular interactions signals the high expectations for improving drug discovery. However, leading companies are already applying AI tools ...
9:00 AM
-
50 minsWith the election of a new Congress, President, and agency leadership, there are questions about the trajectory of policies and guidelines and what will change for the biotech industry. As new priorit ...
10:00 AM
-
50 minsOncology remains one of the top therapeutic areas garnering investor interest, and scientific advances are yielding new approaches that are showing sometimes game-changing clinical promise in treating ...
11:00 AM
-
50 minsAs venture capital remains difficult to reach, the availability of debt financing, royalty financing, family office funding, and other alternative methods, as well as PIPEs for public companies, becom ...
1:00 PM
-
50 minsThe October 2024 approval of the first schizophrenia drug with a new mechanism of action since the 1950s heralds an acceleration of investment interest in supporting new medicines for neuropsychiatric ...
2:00 PM
-
50 minsJohn Maraganore is a co-founder and executive chair of City Therapeutics. He was the founding CEO and a director of Alnylam Pharmaceuticals - the leading RNAi therapeutics company - which he led for n ...
3:00 PM
-
50 minsDespite an extended period of lower biopharma stock valuations and a start of declining interest rates, M&A totals remain historically low. With a new U.S. government administration taking office, and ...
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}